MedPath

Incidence of esophagitis, peptic ulcers and small intestinal mucosal lesions induced by loxoprofen, etodolac and celecoxib in healthy volunteers: a prospective randomized comparative trial

Not Applicable
Recruiting
Conditions
SAID induced gastrointestinal mucosal lesions
Registration Number
JPRN-UMIN000009475
Lead Sponsor
Second Department of Internal Medicine, Osaka Medical College
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
33
Inclusion Criteria

Not provided

Exclusion Criteria

1) Subjects who have active peptic ulcer or gastrointestinal bleeding and need endoscopic treatment immediately 2) Subjects with significant hepatic disease, renal disease, heart disease or respiratory disease 3) Subjects with a history of gastrointestinal surgery other than appendectomy 4) Subjects orally taking or planning to orally take drug other than loxoprofen, etodolac, celecoxib or famotidine 5) Subjects with alcohol or chemical dependencies 6) Subjects with a history of intestinal obstruction, or person with suspected gastrointestinal obstruction on other tests 7)Subjects who cannot agree that surgery may be required if capsule endoscope retained in the body 8) Subjects whom otherwise the investigator determined ineligible as the subject

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The numbers of small intestinal mucosal breaks evaluated by capsule endoscopy
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath